News Release
SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth
May 12, 2025 — SOLVD Health has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.
Aicher’s expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executive experience in genomics, laboratory medicine, and diagnostics innovation. He co-founded and served as CEO of the National Genetics Institute (NGI) — acquired by Labcorp (NYSE: LH) — where he later led the company’s Esoteric Business Units, which generated over $1 billion in annual revenue. He currently serves as Executive Chairman of SemiconBio and on the board of Genetic Signatures (ASX: GSS) and Techcyte. He holds a bachelor’s degree in business administration from the University of Redlands and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.
Cebula’s deep financial acumen and board leadership will help guide SOLVD Health’s expansion and long-term sustainability. An accomplished investor and advisor with extensive experience in private equity, investment banking, and operational transformation, he was a senior asset management executive focused on providing capital to lower middle market companies in the United States and Canada and has served on over fifteen private and public company boards. Cebula has held senior roles at Oaktree Capital Management, Jefferies Capital Partners, and Drexel Burnham Lambert, with a focus on strategic growth and value creation, and graduated from The Wharton School of The University of Pennsylvania.
“As we advance the next phase of our mission — bringing personalized, precision insights to more patients and providers — Mike and Vincent bring the experience and strategic vision to help us scale our impact,” said Dr. Keri Donaldson, Founder and CEO of SOLVD Health. “Mike’s contributions to diagnostics innovation and Vincent’s financial and operational leadership will be instrumental as we grow our platform and deepen our ability to deliver better health outcomes through data.”
These board appointments come at a pivotal time for SOLVD Health as it advances its proprietary diagnostics platform, including the FDA-approved AvertD® test for assessing the genetic risk of opioid use disorder (OUD). With Aicher and Cebula’s assistance, the company is well-positioned to deepen its clinical impact, expand strategic partnerships, and further its mission to prevent disease through data-driven, patient-centered innovation.
About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.
Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com
Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com
